CCDC 986729: Experimental Crystal Structure Determination

Ted W. Johnson(WorldFish), Martin P. Edwards(Pfizer (United States)), Paul Richardson(Pfizer (United States)), Alexei Brooun(Pfizer (United States)), Laura Lingardo(Pfizer (United States)), Huichun Zhu(Pfizer (United States)), Justine L. Lam(Pfizer (United States)), Helen Y. Zou(Centre for Cancer Biology), John C. Kath(Pfizer (United States)), Michele McTigue(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Michael R. Collins(Pfizer (United States)), Judith G. Deal(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Simon Bailey(The University of Melbourne), J. Jean Cui(Southern Medical University), Qinhua Huang(Pfizer (United States)), Lars D. Engstrom(Mirati Therapeutics (United States)), Wei Liu(Nanjing University of Science and Technology), Ya‐Li Deng(Pfizer (United States)), Mingying He(Pfizer (United States)), Robert L. Hoffman(Pfizer (United States)), Graham L. Smith(Pfizer (United States)), Cynthia L. Palmer(Pfizer (United States)), JinJiang Zhu(Pfizer (United States)), Phuong Le, Dac M. Dinh(Pfizer (United States)), Jacqui Hoffman(Pfizer (United States)), Albert Stewart(Pfizer (United States)), Tod Smeal(Pfizer (United States)), Hieu Lam(Pfizer (United States)), Benjamin J. Burke(Pfizer (United States))
The Cambridge Structural Database
January 1, 2014
10.5517/cc123rzx
Cited by 0

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
|Cancer Research|2007|750
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382